Mechanism of Action
B1 and B2 Receptor Signaling
Bradykinin acts on two G protein-coupled receptors. B2 receptors are constitutively expressed on endothelium, smooth muscle, neurons, and fibroblasts, they mediate most of bradykinin's acute biological effects via Gq signaling (IP3/DAG, increased Ca2+, activation of phospholipase A2) and Gi signaling (NO synthesis via eNOS activation). B1 receptors are not normally expressed but are rapidly induced by inflammation, cytokines (IL-1beta, TNF-alpha), and endotoxin, they then contribute to the sustained vascular effects and hyperalgesia of chronic inflammatory states. Prolonged B2 receptor stimulation causes B2 internalization and B1 upregulation, shifting the receptor profile during inflammation.
Vasodilation and NO/Prostacyclin Release
The dominant vascular effect of bradykinin is endothelium-dependent vasodilation mediated by two pathways: (1) eNOS activation via B2-Gq-Ca2+, producing NO which diffuses to smooth muscle causing relaxation; (2) phospholipase A2 activation releasing arachidonic acid, converted to prostacyclin (PGI2) by COX, causing smooth muscle relaxation and platelet anti-aggregation. These effects are the mechanistic basis for ACE inhibitor cardioprotection, by preventing bradykinin degradation, ACE inhibitors amplify these vasodilatory and anti-thrombotic signals. The bradykinin-NO connection is also central to the bradykinin-mediated component of ischemic preconditioning.
Pain Sensitization and Wound Healing
Bradykinin directly activates nociceptors (pain fibers) via B2 receptors on sensory neurons, producing pain and allodynia, and sensitizing TRPV1 (capsaicin receptor) to heat and mechanical stimuli. This is why bradykinin release at injury sites contributes to both initial pain and inflammatory hyperalgesia. Paradoxically, at wound sites this pain signaling serves a protective function. The wound healing actions involve bradykinin-stimulated release of EGF, IGF-1, and VEGF from keratinocytes and fibroblasts, promoting the proliferative phase of tissue repair. B2 receptor activation on fibroblasts also directly stimulates collagen synthesis.
Research Summary
ACE Inhibitors and Cardioprotection
Most StudiedThe bradykinin contribution to ACE inhibitor benefit is established by studies showing that B2 receptor blockade (icatibant) partially attenuates ACE inhibitor-mediated improvements in endothelial function, cardiac protection after MI, and blood pressure-independent cardioprotective effects. The HOPE trial's ramipril benefit beyond blood pressure reduction is partly attributed to bradykinin-mediated NO production and ischemic preconditioning. This bradykinin-cardioprotection connection is one of the most clinically relevant aspects of kinin biology.
Wound Healing and Regenerative Medicine
Moderate EvidenceLocal bradykinin application promotes re-epithelialization, fibroblast proliferation, and collagen synthesis in wound models. Studies show intraarticular bradykinin reduces cartilage degradation in early OA models via NO-mediated signaling. The growth factor-releasing action of bradykinin (stimulating EGF, VEGF, HGF) positions it as a potential autocrine/paracrine wound-healing enhancer, though its extreme short half-life makes sustained local delivery challenging.
Hereditary Angioedema Biology
RegulatoryHAE (hereditary angioedema type I and II) is caused by C1-esterase inhibitor deficiency, leading to uncontrolled kallikrein activation and bradykinin overproduction, causing potentially fatal soft tissue swelling. Icatibant (B2 antagonist), kallikrein inhibitors (ecallantide, lanadelumab), and C1-INH replacement are FDA-approved treatments. This disease validates bradykinin as the primary mediator of angioedema and provides the most direct human evidence for bradykinin's acute vascular effects.
Calculate your Bradykinin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Local wound healing (research) | 1-10 mcg/mL in wound irrigation | Topical application during wound care | Topical/local |
| Intraarticular (joint research) | 1-5 mcg intraarticular | Single or periodic injection | Intraarticular |
| Vascular research (forearm infusion) | 100-500 ng/min intra-arterial | Research infusion protocol | Intra-arterial (research only) |
Bradykinin's plasma half-life of 15-30 seconds makes systemic injectable use impractical for most research purposes, it must be given by continuous IV infusion or locally. ACE inhibitors or neutral endopeptidase inhibitors can be used to extend bradykinin half-life in vivo (converting exogenous bradykinin to a more sustained effect). For wound healing applications, use a slow-release formulation or surface-adsorbed delivery vehicle to maintain local concentrations.
Interactions
Safety Profile
Bradykinin's extreme potency and short half-life make it difficult to use safely in systemic contexts. IV bradykinin at pharmacological doses causes: severe hypotension, reflex tachycardia, bronchospasm (B2 receptor on airway smooth muscle), flushing, and pain. Local and topical applications at low concentrations are generally well-tolerated, consistent with bradykinin's role as a physiological local signaling molecule. The risk of angioedema with systemic administration (even at low doses) is significant, particularly in patients with ACE inhibitor co-administration or subclinical C1-INH deficiency. The B2 receptor's pain-sensitizing action makes high-dose local bradykinin application painful. Not WADA prohibited. Not scheduled.
References
- [1]Rocha e Silva M et al. "Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin." Am J Physiol. 1949;156(2):261-273.
- [2]Yusuf S et al. "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE)." N Engl J Med. 2000;342(3):145-153.
- [3]Cicardi M et al. "Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema." N Engl J Med. 2010;363(6):532-541.